Slide 1: Protein degraded. Disease targeted. Lives transformed.
Protein degraded. Disease targeted. Lives transformed. September 2026 Exhibit 99.2
Slide 2: Forward-looking Statements and Intellectual Property
Forward-looking Statements and Intellectual Property 2 FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,
Slide 3: Advancing Differentiated TPD Medicines and Building a Sustainable Pipeline of High-value Degraders
Advancing Differentiated TPD Medicines and Building a Sustainable Pipeline of High-value Degraders To Achieve Our Vision 3© 2026 C4 Therapeutics, Inc. STRATEGY: DEVELOP BEST-IN-CLASS AND FIRST-IN-CLASS DEGRADERS. VALIDATED PATHWAYS. LARGE MARKET OPPORTUNITIES Multiple myeloma (MM);Targeted Protein D
Slide 4: C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders
C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders Across Clinical Oncology Portfolio and INN Discovery Strategy © 2026 C4 Therapeutics, Inc. Advance potential best- in-class and first-in-class degraders • Enroll 2 clinical trials with cemsidomide to address 2L+ and 4L+
Slide 5: Focused Pipeline Advancing Clinical Oncology Degraders and New Discovery Strategy in INN
Focused Pipeline Advancing Clinical Oncology Degraders and New Discovery Strategy in Inflammation, Neuroinflammation & Neurodegeneration (INN) Diseases 5© 2026 C4 Therapeutics, Inc. INN DISCOVERY Discovery Novel targets in pathways of: -IL-23/IL-17 -Type 1 IFN -MAPK, PI3K/AKT, NF-kB INN Inflammation
Slide 6: Strategic Platform Collaborations Expand Potential Reach of C4T TPD Medicines
Strategic Platform Collaborations Expand Potential Reach of C4T TPD Medicines 6© 2026 C4 Therapeutics, Inc. 1. Earned and received preclinical milestones in Q1 2025 2. Delivered development candidates to Biogen in Q1 2025 and Q3 2024. In Q3 2025, the IRAK4 degrader, BIIB142, entered Phase 1 clinical
Slide 7: Cemsidomide
Cemsidomide Cereblon-modulating protein degrader of IKZF1/3 Multiple Myeloma
Slide 8: Cemsidomide is Positioned for Success
Cemsidomide is Positioned for Success © 2026 C4 Therapeutics, Inc. Multiple myeloma (MM); IMiDs® are registered trademarks of BMS Cemsidomide has a potential best-in-class profile among other IKZF1/3 degraders, with a clinically de-risked MOA Potential best-in-class profile Cereblon-modulating prote
Slide 9: IKZF1/3 are Transcription Factors Central to Multiple Myeloma Development and Progression
IKZF1/3 are Transcription Factors That are Central Drivers of Multiple Myeloma Development and Progression © 2026 C4 Therapeutics, Inc. Multiple myeloma (MM) 9 Physiological Functions: • IKZF1/3 directly regulate the activity of IRF4, another transcription factor that regulates downstream immune cel
Slide 10: Biology of IKZF1/3 Degradation Supports Use Across Lines of Therapy and Combination Regimens
Biology of IKZF1/3 Degradation Supports Use Across Lines of Therapy and Combination Regimens 10 ~11K MM patient deaths expected in the U.S. in 20263 ~40% MM patients do not survive beyond five years, despite recent treatment advances4 ~$59B Total projected MM market in U.S., Japan, EU4+UK by 20342 2
Slide 11: Cemsidomide demonstrated potential best-in-class profile in Phase 1 trial
• Cemsidomide demonstrated potential best-in-class profile in a Phase 1 trial in heavily pre-treated RRMM patients • Cemsidomide advancing in Phase 2 MOMENTUM trial in 4L+ & Phase 1b combo w/ elranatamab1 • Mezigdomide and iberdomide in late- stage trials: SUCCESSOR-1; SUCCESSOR- 2; EXCALIBER NDMM •
Slide 12: Cemsidomide is a Potential Best-in-Class Cereblon-modulating Protein Degrader of IKZF1/3
Cemsidomide is a Potential Best-in-Class Cereblon-modulating Protein Degrader of IKZF1/3 in Multiple Myeloma 12© 2026 C4 Therapeutics, Inc. Highly potent & selective IKZF1/3 degrader High target specificity Does not degrade off-target neosubstrates1, including CK1𝛼 and GSPT1 No renal clearance…
Slide 13: Phase 1 Trial of Cemsidomide + Dexamethasone Enrolled a Heavily Pre-treated Population
Phase 1 Trial of Cemsidomide + Dexamethasone Enrolled a Heavily Pre-treated Patient Population with Majority Receiving Prior CAR-T or T-cell Engager Therapy 13© 2026 C4 Therapeutics, Inc. Characteristics Safety Population (N=73) Prior therapies, median (range) 7 (3-22) Prior CAR-T therapy, n (%) 37
Slide 14: Cemsidomide + Dexamethasone Demonstrated a Well-tolerated Profile
Cemsidomide + Dexamethasone Demonstrated a Well-tolerated Profile With Minimal Dose Reductions and Discontinuations 14© 2026 C4 Therapeutics, Inc. Hematologic and Infection TEAEs, n (%) All Grades (N=73) Grade 3 (N=73) Grade 4 (N=73) Grade 5 (N=73) Neutropenia 45 (62) 16 (22) 26 (36) 0 Infections Pn
Slide 15: Cemsidomide + Dexamethasone Demonstrated Deep and Durable Responses
Cemsidomide + Dexamethasone Demonstrated Deep and Durable Responses Across the Highest Two Dose Levels 15© 2026 C4 Therapeutics, Inc. 14% (10) 7% (1) 15% (3) 16% (3) 36% (26) 47% (7) 30% (6) 21% (4) 14% (10) 20% (3) 15% (3) 11% (2) 24% (17) 20% (3) 35% (7) 26% (5) 7% (5) 7% (1) 5% (1) 11% (2c) 3% (2
Slide 16: Cemsidomide Has the Potential to Be a Foundational Treatment Across Multiple Lines of Multiple Myeloma
Cemsidomide Has the Potential to Be a Foundational Treatment Across Multiple Lines of Multiple Myeloma 16© 2026 C4 Therapeutics, Inc. Late-line Opportunity Combination with dexamethasone R A T I O N A L E • Only cereblon-modulating protein degrader of IKZF1/3 with a label-enabling development strate
Slide 17: Preliminary Phase 1b Biomarker Data Supportive of Mechanistic Rationale for Combining with Immune-Based Therapies
Preliminary Phase 1b Biomarker Data is Supportive of Cemsidomide’s Mechanistic Rationale for Combining with Immune-Based Therapies 17© 2026 C4 Therapeutics, Inc. • Demonstrated t-cell activation across clinically relevant doses as a monotherapy and in combination w/ dexamethasone3 BIOMARKER DATA FRO
Slide 18: First Cemsidomide Dose Level in Phase 1b Trial with Elranatamab Declared Safe
First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe; Advancing Trial to Dose Expansion and Escalation Cohorts © 2026 C4 Therapeutics, Inc. 1 Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase
Slide 19: Phase 2 MOMENTUM Trial of Cemsidomide + Dexamethasone in 4L+ MM Continues to Progress
Phase 2 MOMENTUM Trial of Cemsidomide + Dexamethasone in 4L+ MM Continues to Progress © 2026 C4 Therapeutics, Inc. Dexamethasone (dex); Overall response rate (ORR); Fourth line (4L); Recommended Phase 2 dose (RP2D); Overall response (ORR); International Myeloma Working Group (IMWG); Once daily (QD)
Slide 20: Discovery: Inflammation, Neuroinflammation & Neurodegeneration (INN)
Discovery Inflammation, Neuroinflammation & Neurodegeneration (INN)
Slide 21: New Discovery Strategy Focused on INN with First-in-Class Potential
New Discovery Strategy Focused on Inflammation, Neuroinflammation & Neurodegeneration (INN) with First-in-Class Potential in Clinically Validated Pathways Uniquely Suited for TPD 21© 2026 C4 Therapeutics, Inc. Targeted Protein Degradation (TPD); Central nervous system (CNS) Leveraging C4T’s success
Slide 22: Focused on INN to Address High Unmet Needs in a Large Patient Population
Focused on Inflammation, Neuroinflammation & Neurodegeneration (INN) to Address High Unmet Needs in a Large Patient Population with a Clear TPD Advantage © 2026 C4 Therapeutics, Inc. Central nervous system (CNS); Pharmacodynamic (PD); Targeted Protein Degradation (TPD); Mechanism of action (MOA) 1Ba
Slide 23: Potential for Degraders To Be the Optimal Therapeutic Modality for CNS Diseases Over Inhibitors
Potential for Degraders To Be the Optimal Therapeutic Modality for CNS Diseases Over Inhibitors 23 Theoretical Inhibitor and Degrader Brain PK Curves for Molecules With Similar Efficacy* (Illustrative graphic) *For target proteins with a long resynthesis rate Lower exposure levels for highly catalyt
Slide 24: Pursuing Targets in Validated Pathways With Application to a Broad Set of Indications
Pursuing Targets in Validated Pathways With Application to a Broad Set of Indications © 2026 C4 Therapeutics, Inc. *Highlights indications that are central nervous system diseases Image 1 Zheng M-Y, Luo L-Z Int. J. Mol. Sci. 2025; Image 2:Lukhele S, et al. Semin Immunol 2019; Image 3Liu T, et al, Si
Slide 25: C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders
C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders Across Clinical Oncology Portfolio and INN Discovery Strategy © 2026 C4 Therapeutics, Inc. Advance potential best-in-class and first-in-class degraders • Enroll 2 clinical trials with cemsidomide to address 2L+ and 4L+